New hope for kids with psoriasis: cosentyx® shows promise in chinese study

NCT ID NCT05388916

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx® (secukinumab) for up to 52 weeks. The goal was to see how safe and effective the drug is in real-world settings. Researchers tracked side effects and measured how much the psoriasis improved using a standard skin score.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS

Contacts and locations

Locations

Novartis Investigative Site

Guangzhou, Guangdong, 510091, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site

Zhengzhou, Henan, 450018, China
Novartis Investigative Site

Shenyang, Liaoning, 110004, China
Novartis Investigative Site

Xian, Shanxi, 710004, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310009, China
Novartis Investigative Site

Beijing, 100069, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.